Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan®☆,☆☆
Graphical abstract
The synthesis and biological results for metabolites of the above vasopressin agonist 1 and antagonist 2 are presented.
Section snippets
Acknowledgments
We thank Drs. Magid Abou-Gharbia, Ron Magolda, Jay Wrobel, and Jeffrey Pelletier for support and encouragement. We thank Drs. Walter Spinelli and C. H. Park for additional biological data. We also thank Dr. Michael Kagan for valuable scientific suggestions and the assistance of the Department of Analytical Chemistry for analytical data.
References and notes (15)
Hepatology
(2003)Hepatology
(2002)J. Lab. Clin. Med.
(2001)Ann. Rep. Med. Chem
(2001)Adv. in Experimental Med. & Biol
(1998)- et al.
Ann. Rev. Physiol
(1994) Drugs Future
(2002)
Cited by (12)
Promotional effect of palladium in Co-SiO<inf>2</inf> core@shell nanocatalysts for selective liquid phase hydrogenation of chloronitroarenes
2020, Journal of CatalysisCitation Excerpt :Functionalized arylamines have been used for long time as the starting point of a wide range of building blocks products with different applications and they are largely synthetized by the selective reduction of their nitro-derivate precursors [1,2]. Among them, halo-nitroarenes are taken as raw materials in the production of halo-arylamines used in production of commercial drugs such as Linezolid (antibiotic) [3], Loxapine (antiphsycotic) [4], Lapatinib (antineoplastic for breast cancer treatment) [5], Lixivaptan (treatment and prevention of cardiovascular diseases) [6,7], Sorafenib (antineoplastic for kidney cancer treatment) [8], chloroprocaine (anesthetic effect) [9] and others. The main synthetic strategy reported is the catalytic reduction of NO2 group by heterogeneous hydrogenation employing H2 as reducing agent or transfer hydrogenation using hydrogen donors like hydrazine, formic acid, or NaBH4 [1,2,10].
Facile synthesis of 1,2,3-triazole-fused indolo- and pyrrolo[1,4]diazepines, DNA-binding and evaluation of their anticancer activity
2019, Bioorganic ChemistryCitation Excerpt :Benzo[e]pyrrolo[1,2-a][1,2,3]triazolo[5,1-c][1,4]diaze-pin-8(4H)-one is known to exhibit protease inhibitory activity, (+)-JQ-1 [13] and I-BET762 [14] are potent inhibitors of bromodomain and extra-C terminal domain (BET) proteins. Benzo-pyrido-triazolo-diazepines [15] are used as effective anti-cancer compounds. Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) exert their cytotoxic and antitumor activity through covalent binding to DNA [16,17] (Fig. 1).
Synthesis and evaluation of azabicyclo[3.2.1]octane derivatives as potent mixed vasopressin antagonists
2010, Bioorganic and Medicinal Chemistry LettersChapter 7: Seven-membered rings
2009, Progress in Heterocyclic ChemistryCitation Excerpt :In the fields of allergy and respiration, examples include 2-oxo-3-aminoazepine derivatives which act as dual neurokinin (tachykinin) NK1/NK2 receptor probes for development of options for treatment of asthsma and other airway diseases <07BMCL890> and benzo[1,5]diazepine derivatives as new non-steroidal inhibitors of 17-β-hydroxysteroid dehydrogenase, an enzyme associated with hormone-dependent and neuronal diseases <07JEIMC29>. For the fields of sexual health/urology/gastrointestinal, examples include a benzoxazepinone small molecule antagonist of the parathyroid hormone receptor for identification of small molecule treatments of postmenopausal osteoporosis <07PNAS6846>, a metabolite of vasopression V2-receptor agonist WAY-151932, which has undergone clinical trials for nocturnal enuresis, was found to be biologically equipotent with its clinical lead <07BMCL5796> and 1,4-benzodioxepine derivatives as a novel class of muscarinic receptor antagonists selective for the M3 receptor that display selectivity for the bladder over the salivary gland <07BMCL925>. Tri-and tetra-hydroxyazepanes were shown to be potent glycosidase inhibitors <07JOC4258> while isofagomine tetrahydroxyazepane hybrids were synthesised as β-glucosidase or mannosidase inhibitors <07CC183>.
- ☆
Currently licensed by Wyeth to Cardiokine, Inc., Philadelphia, PA 19102, USA. Tel.: +1 215 399 1200; fax: +1 215 399 1230.
- ☆☆
Presented in preliminary form at the ACS 38th National Organic Symposium, Indiana University, Bloomington, IN, USA, June 8–12, 2003.